108524-68-1

Usage

Uses

Used in Pharmaceutical Industry:
Benzenebutanoic acid, a-[[(1,1-dimethylethoxy)carbonyl]amino]is used as a building block for the synthesis of peptides due to its ability to protect the amino group of amino acids. This protection enables selective reactions and increased yields in the creation of complex peptides, which are essential for developing new drugs and therapeutic agents.
Used in Biotechnology Industry:
In the biotechnology sector, Benzenebutanoic acid, a-[[(1,1-dimethylethoxy)carbonyl]amino]serves as a key component in the development of peptide-based products. Its protective Boc group allows for the controlled synthesis of peptides with specific functions, which can be utilized in various biotechnological applications, such as diagnostics, therapeutics, and research tools.

Upstream product

• 116611-56-4 tert-butyl (R)-(1-hydroxy-4-phenylbutan-2-yl)carbamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 75553-23-0 (E)-5-phenyl-2-penten-1-ol 
• 91-00-9 Benzhydrylamine 
• 240420-40-0 tert-butyl (4R)-2,2-dimethyl-4-(2-phenylethyl)-1,3-oxazolidine-3-carboxylate 
• 108-86-1 bromobenzene 
• 132652-65-4 tert-butyl 2,2-dimethyl-4-[(E)-2-phenylethenyl]-1,3-oxazolane-3-carboxylate 
• 2766-43-0 N-tert-butyloxycarbonyl-L-serine methyl ester 
• 116611-49-5 ((S)-1-Hydroxymethyl-2-phenylsulfanyl-ethyl)-carbamic acid tert-butyl ester 
• 116696-85-6 (2S)-2-t-butoxycarbonylamino-3-phenylsulfonyl-1-(2-tetrahydropyranyloxy)propane 
• 116611-63-3 methyl N-(tert-butoxycarbonyl)-O-(tetrahydro-2H-pyran-2-yl)-L-serinate 
• 116611-50-8 ((S)-2-Benzenesulfonyl-1-hydroxymethyl-ethyl)-carbamic acid tert-butyl ester 
• 116611-60-0 ((S)-2-Benzenesulfonyl-1-hydroxymethyl-3-phenyl-propyl)-carbamic acid tert-butyl ester 
• 116611-51-9 [(S)-2-Benzenesulfonyl-3-phenyl-1-(tetrahydro-pyran-2-yloxymethyl)-propyl]-carbamic acid tert-butyl ester 

Downstream Products

• 162126-44-5 (3-phenyl-1-{[2'-(1-trityl-1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-carbamoyl}-propyl)-carbamic acid tert-butyl ester 
• 240420-27-3 methyl (2R)-2-[(tert-butoxycarbonyl)amino]-4-phenylbutanoate 
• 116611-56-4 tert-butyl (R)-(1-hydroxy-4-phenylbutan-2-yl)carbamate 
• 233690-65-8 (4-{1-[(1H-benzoimidazol-2-yl)-hydroxy-methyl]-3-phenyl-propylcarbamoyl}-4-tert-butoxycarbonylamino-butyl)-carbamic acid tert-butyl ester 
• 233690-63-6 (4-tert-butoxycarbonylamino-4-{1-[(5-chloro-benzooxazol-2-yl)-hydroxy-methyl]-3-phenyl-propylcarbamoyl}-butyl)-carbamic acid tert-butyl ester 
• 233690-60-3 (4-tert-butoxycarbonylamino-4-{1-[(5,6-dimethyl-benzooxazol-2-yl)-hydroxy-methyl]-3-phenyl-propylcarbamoyl}-butyl)-carbamic acid tert-butyl ester 
• 233690-84-1 (4-tert-butoxycarbonylamino-6-{1-[(5,6-dimethyl-benzooxazol-2-yl)-hydroxy-methyl]-3-phenyl-propylamino}-5-hydroxy-hexyl)-carbamic acid tert-butyl ester 
• 233690-41-0 (4-tert-butoxycarbonylamino-4-{1-[4-(naphthalen-2-ylcarbamoyl)-oxazol-2-yl]-3-phenyl-propylcarbamoyl}-butyl)-carbamic acid tert-butyl ester 
• 233690-47-6 (4-tert-butoxycarbonylamino-4-{3-phenyl-1-[4-(quinolin-3-ylcarbamoyl)-oxazol-2-yl]-propylcarbamoyl}-butyl)-carbamic acid tert-butyl ester 
• 233690-80-7 (4-tert-butoxycarbonylamino-5-hydroxy-6-{3-phenyl-1-[4-(quinolin-3-ylcarbamoyl)-oxazol-2-yl]-propylamino}-hexyl)-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Fluorovinylsulfones and -Sulfonates as Potent Covalent Reversible Inhibitors of the Trypanosomal Cysteine Protease Rhodesain: Structure-Activity Relationship, Inhibition Mechanism, Metabolism, and in Vivo Studies

Rhodesain is a major cysteine protease of Trypanosoma brucei rhodesiense, a pathogen causing Human African Trypanosomiasis, and a validated drug target. Recently, we reported the development of α-halovinylsulfones as a new class of covalent reversible cysteine protease inhibitors. Here, α-fluorovinylsulfones/-sulfonates were optimized for rhodesain based on molecular modeling approaches. 2d, the most potent and selective inhibitor in the series, shows a single-digit nanomolar affinity and high selectivity toward mammalian cathepsins B and L. Enzymatic dilution assays and MS experiments indicate that 2d is a slow-tight binder (Ki = 3 nM). Furthermore, the nonfluorinated 2d-(H) shows favorable metabolism and biodistribution by accumulation in mice brain tissue after intraperitoneal and oral administration. The highest antitrypanosomal activity was observed for inhibitors with an N-terminal 2,3-dihydrobenzo[b][1,4]dioxine group and a 4-Me-Phe residue in P2 (2e/4e) with nanomolar EC50 values (0.14/0.80 μM). The different mechanisms of reversible and irreversible inhibitors were explained using QM/MM calculations and MD simulations.

Synthesis ofN-Boc-α-amino Acids from Carbon Dioxide by Electrochemical Carboxylation ofN-Boc-α-aminosulfones

Electrochemical reduction ofN-Boc-α-aminosulfones in DMF using an undivided cell equipped with a Pt plate cathode and an Mg rod anode under atmospheric pressure of bubbling carbon dioxide through the solution under constant current conditions resulted in a reductive C-S bond cleavage with elimination of benzenesulfinate ion generating the corresponding anion species followed by fixation of carbon dioxide to give the correspondingN-Boc-α-amino acids in moderate to good yields.

N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS

The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.

Quantum Chemical-Based Protocol for the Rational Design of Covalent Inhibitors

We propose a structure-based protocol for the development of customized covalent inhibitors. Starting from a known inhibitor, in the first and second steps appropriate substituents of the warhead are selected on the basis of quantum mechanical (QM) computations and hybrid approaches combining QM with molecular mechanics (QM/MM). In the third step the recognition unit is optimized using docking approaches for the noncovalent complex. These predictions are finally verified by QM/MM or molecular dynamic simulations. The applicability of our approach is successfully demonstrated by the design of reversible covalent vinylsulfone-based inhibitors for rhodesain. The examples show that our approach is sufficiently accurate to identify compounds with the desired properties but also to exclude nonpromising ones.

N-alkoxyamide conjugates as imaging agents

The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.

Development of novel dipeptide-like rhodesain inhibitors containing the 3-bromoisoxazoline warhead in a constrained conformation

Novel dipeptide-like rhodesain inhibitors containing the 3-bromoisoxazoline warhead in a constrained conformation were developed; some of them possess Ki values in the micromolar range. We studied the structure-activity relationship of these derivatives and we performed docking studies, which allowed us to find out the key interactions established by the inhibitors with the target enzyme. Biological results indicate that the nature of the P2 and P3 substituents and their binding to the S2/S3 pockets is strictly interdependent.

Synthesis of γ-oxo γ-aryl and γ-aryl α-amino acids from aromatic aldehydes and serine

γ-Oxo α-amino acids and γ-aryl α-amino acids are compounds with very interesting biological properties and are active components of many drug molecules. Oxo amino acids are also used as synthetic precursors for a number of unnatural amino acids and amino alcohols. We report a very efficient synthesis of such compounds through the coupling of aromatic dithianes, prepared from aromatic aldehydes and an iodide derivative of serine. The dithiane groups in compounds thus obtained can be either hydrolyzed or reduced to generate 4-oxo-4-aryl or 4-aryl 2-amino butanol derivatives, respectively, which, on further transformations, can be converted into the title compounds. Starting with L-serine provides the corresponding D-amino acids with complete enantiopurity. The reported method is economically viable and complements the existing methods, which rely largely on cross-coupling reactions.

N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS

The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.

ALPHA-SUBSTITUTED N-SULFONYL GYLCINE AMIDES ANTAGONISTS OF CCR10, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR USING THEM

Disclosed is a compound of formula (I). Wherein R1, R2 Ar and Cy are as defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions of the compound of formula (I), methods of making t

Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith

Provided herein are Heterocyclic Compounds having the following structure: wherein R1, R2, X, Y and Z are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heterocyclic Compound to a patient in need thereof.